Global Overt Hepatic Encephalopathy Market Size, Status and Forecast 2019-2025

Hepatic encephalopathy (HE) is an altered level of consciousness as a result of liver failure. Onset may be gradual or sudden. Other symptoms may include movement problems, changes in mood, or changes in personality. In the advanced stages it can result in a coma.
Overt hepatic encephalopathy develops in approximately 40% of patients with cirrhosis during their clinical care. A first episode of overtencephalopathy predicts recurrence in 40% of patients. Aggravating factors for the development of hepatic encephalopathy in advanced liver disease include infection, gastrointestinal bleeding, metabolic disturbance, and receipt of sedative medications. Genetic abnormalities affecting ammonia metabolism can also play a role.
In 2018, the global Overt Hepatic Encephalopathy market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Overt Hepatic Encephalopathy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Overt Hepatic Encephalopathy development in United States, Europe and China.

The key players covered in this study
Alfa Wassermann
Cosmo Pharmaceuticals
Horizon Pharma
KannaLife Sciences
Ocer Therapeutics
Rebiotix
Spherium Biomed
Umecrine Cognition
ASKA Pharmaceutical
Mallinckrodt
Valeant

Market segment by Type, the product can be split into
Covert
Overt

Market segment by Application, split into
Hospitals
Research Institutes
Clinics
Surgical Centers

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Overt Hepatic Encephalopathy status, future forecast, growth opportunity, key market and key players.
To present the Overt Hepatic Encephalopathy development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Overt Hepatic Encephalopathy are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.